| Business Summary | | Neurocrine
Biosciences,
Inc.
is
a
product-based
biopharmaceutical
company
focused
on
neurologic
and
endocrine
diseases
and
disorders.
The
Company's
product
candidates
address
pharmaceutical
markets
such
as
insomnia,
anxiety,
depression,
cancer
and
diabetes.
The
Company's
product
candidates
include
gamma
amino-butyric
acid
(GABA)-A
Agonist,
Corticotropin-Releasing
Factor,
IL-4
Fusion
Toxin,
Altered
Peptide
Ligands
and
Gonadotropin-Releasing
Hormone
Receptor.
The
Company's
research
products
include
Excitatory
Amino
Acid
Transporters,
CRF
R1
Peripheral
Uses,
CRF
R2
Antagonists,
CRF
R2
Agonists/Urocortin
Agonist,
Melanocortin
Receptor
Agonists/Antagonists,
Melanin-Concentrating
Hormone
Antagonists
and
Hypocretin. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NBIX
is
a
neuroimmunology
company
focused
on
the
discovery
and
development
of
novel
therapeutics
to
treat
diseases
and
disorders
of
the
central
nervous
and
immune
systems.
For
the
six
months
ended
6/30/01,
revenues
increased
19%
to
$6.8
million.
Net
loss
totaled
$24.8
million,
up
from
$11.2
million.
Revenues
benefitted
from
revenues
received
under
the
Taisho
Pharmaceuticals
Co.
agreement.
Net
loss
reflects
higher
R&D
expenses
due
to
additional
scientific
personnel. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Joseph Mollica, Ph.D, 60 Chairman | -- | Gary Lyons, 50 Pres,
CEO | $551K | Paul Hawran, 49 CFO,
Exec. VP | 383K | Margaret Valeur-Jensen, Ph.D, 44 Sr.
VP, Gen. Counsel, Sec. | 303K | D. Bruce Campbell, Ph.D, 56 Sr.
VP of Devel. | 322K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|